Fetal insemination is a non-invasive procedure aimed at detecting genetic abnormalities before birth and non-invasive non-surgical screening for abnormalities in the fetus after birth. An in vitro fertilization procedure (IVF) is performed by exposing the patient's eggs to ovarian cysts containing living sperm. If no live sperm are present, then the eggs are retrieved and processed for in vitro culture in the laboratory. The process allows the collection of mature eggs, which are then tested for abnormalities using sophisticated procedures and analyzed using computerized tomography, ultrasound, magnetic resonance imaging, or X-ray technologies.
Increasing risk of chromosomal abnormalities due to growing maternal age and increasing preference for non-invasive techniques over invasive methods are the key factor driving the market growth. According to the World Health Organization, an estimated 295 000 newborns die within 28 days of birth every year, worldwide, due to congenital anomalies. Congenital anomalies can contribute to long-term disability, which may have significant impacts on individuals, families, health-care systems, and societies. Moreover, growing awareness regarding Non-Invasive Prenatal Testing Market (NIPT) is also expected to augment the market growth. The growing focus of diagnostic laboratories to offer safe and effective prenatal tests is further projected to foster market growth.
North America is expected to exhibit significant growth over the forecast period and this is attributed to the increasing research and development activities in the field of chromosomal abnormalities. Also, continuous product innovation by the key manufacturer in the region is again expected to augment market growth. For instance, in August 2019, Axia Women's Health, the nation's independent women's healthcare group announces the launch of non-invasive prenatal testing (NIPT), the first of its kind in a U.S. OB/GYN physician-owned laboratory.
Key Developments:
In June 2017, LifeCodexx AG, a pioneer in non-invasive prenatal DNA testing in Europe has announced its partnership with LifeCell – India’s mother & baby preventive health care provider, to bring PrenaTesT® qNIPTTM testing for the first time to India.
In December 2020, Yourgene announced the launch of ‘IONA Nx NIPT’ workflow, a non-invasive prenatal test (NIPT)
In June 2019, BGI Genomics and Eluthia have announced the launch of a non-invasive prenatal test, the NIFTY® test, under the brand name PreviaTest® in Germany.
In April 2019, Progenity, Inc., announced the launch of the Resura® Prenatal Test for Monogenic Disease, the first of its kind, commercially available, customizable, noninvasive prenatal test (NIPT) for single-gene disorders.
In December 2020, Yourgene announced the launch of ‘IONA Nx NIPT’ workflow, a non-invasive prenatal test (NIPT)
In June 2019, BGI Genomics and Eluthia have announced the launch of a non-invasive prenatal test, the NIFTY® test, under the brand name PreviaTest® in Germany.
In April 2019, Progenity, Inc., announced the launch of the Resura® Prenatal Test for Monogenic Disease, the first of its kind, commercially available, customizable, noninvasive prenatal test (NIPT) for single-gene disorders.
No comments:
Post a Comment